KLP Kapitalforvaltning AS Invests $4.44 Million in Moderna, Inc. (NASDAQ:MRNA)

KLP Kapitalforvaltning AS purchased a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 106,800 shares of the company's stock, valued at approximately $4,441,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. State Street Corp lifted its holdings in Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after buying an additional 1,823,276 shares during the period. Wellington Management Group LLP lifted its stake in Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock worth $349,166,000 after acquiring an additional 906,114 shares during the period. Amundi boosted its holdings in Moderna by 79.8% in the fourth quarter. Amundi now owns 1,206,273 shares of the company's stock valued at $52,075,000 after acquiring an additional 535,273 shares in the last quarter. Two Sigma Advisers LP purchased a new position in Moderna during the 3rd quarter valued at $23,825,000. Finally, Douglas Lane & Associates LLC raised its holdings in Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company's stock worth $32,175,000 after purchasing an additional 298,715 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MRNA. Evercore ISI set a $50.00 target price on shares of Moderna in a research note on Friday, February 14th. Bank of America reduced their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Berenberg Bank raised their target price on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday, January 16th. Royal Bank of Canada restated a "sector perform" rating and set a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. Finally, The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $59.00.

Remove Ads

Moderna Trading Down 2.7 %

NASDAQ:MRNA traded down $0.86 during mid-day trading on Friday, reaching $31.26. The company's stock had a trading volume of 3,030,558 shares, compared to its average volume of 6,796,689. The firm's fifty day moving average price is $34.78 and its two-hundred day moving average price is $44.93. The stock has a market cap of $12.09 billion, a P/E ratio of -3.36 and a beta of 1.86. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.